|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013089,
umls-concept:C0017200,
umls-concept:C0018802,
umls-concept:C0031082,
umls-concept:C0150369,
umls-concept:C0232164,
umls-concept:C0521116,
umls-concept:C0681698,
umls-concept:C0876994,
umls-concept:C1414461,
umls-concept:C1708528
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2003-4-3
|
|
pubmed:abstractText |
Congestive heart failure (CHF) is among the most serious toxicities of doxorubicin, a potent cancer chemotherapeutic agent. Serial left ventricular ejection fraction (LVEF) monitoring during doxorubicin therapy for preventing CHF was proposed over 20 years ago. The current utility and cost-effectiveness of this approach in the present era are not known.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1071-3581
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
132-9
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12673177-Antineoplastic Agents,
pubmed-meshheading:12673177-Cost-Benefit Analysis,
pubmed-meshheading:12673177-Doxorubicin,
pubmed-meshheading:12673177-Gated Blood-Pool Imaging,
pubmed-meshheading:12673177-Heart,
pubmed-meshheading:12673177-Heart Failure,
pubmed-meshheading:12673177-Humans,
pubmed-meshheading:12673177-Middle Aged,
pubmed-meshheading:12673177-Neoplasms,
pubmed-meshheading:12673177-Retrospective Studies,
pubmed-meshheading:12673177-Risk Assessment,
pubmed-meshheading:12673177-Stroke Volume,
pubmed-meshheading:12673177-United States
|
|
pubmed:articleTitle |
Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era.
|
|
pubmed:affiliation |
Department of Medicine, Yale University School of Medicine, New Haven, Conn., USA.
|
|
pubmed:publicationType |
Journal Article,
Evaluation Studies
|
